benazepril

Benazepril inhibits the activity of circulating angiotensin-converting enzyme (ACE) in horses.

Benazepril-d5 HCl is a deuterated compound of Benazepril HCl. Benazepril HCl has a CAS number of 86541-74-4. Benazepril is an angiotensin-converting enzyme (ACE) inhibitor widely used in the therapy of hypertension. Benazepril is associated with a low rate of transient serum aminotransferase elevations and has been linked to rare instances of acute liver injury.

Benazepril hydrochloride (CGS 14824A HCl) is an angiotensin-converting enzyme (ACE) inhibitor widely used in the therapy of hypertension. Benazepril hydrochloride is associated with a low rate of transient serum aminotransferase elevations and has been linked to rare instances of acute liver injury.

Benazeprilat-d5 is a deuterated compound of Benazeprilat. Benazeprilat has a CAS number of 86541-78-8. Benazeprilat(CGS 14831) is an orally active active metabolite of Benazepril.Benazeprilat has potent antihypertensive activity and can be used in combination with other classes of compounds, including thiazide diuretics and calcium channel blockers, to reduce the incidence of diseases associated with cardiovascular risk and secondary end-organ damage.Benazeprilat may be be used to study acute left ventricular failure.

Benazeprilat(CGS 14831) is an orally active active metabolite of Benazepril.Benazeprilat has potent antihypertensive activity and can be used in combination with other classes of compounds, including thiazide diuretics and calcium channel blockers, to reduce the incidence of diseases associated with cardiovascular risk and secondary end-organ damage.Benazeprilat may be be used to study acute left ventricular failure.

CGP-42456A - Benazepril Related Compound A, it is an Impurity. Benazepril is a prodrug which is metabolized by the liver into its active form benazeprilat via cleavage of the drug's ester group. Benazepril and Benazeprilat inhibit angiotensin-converting enzyme (ACE) in human subjects and animals. Benazeprilat has much greater ACE inhibitory activity than does Benazepril. It is indicated for the treatment of hypertension.

Infigratinib mesylate, also known as, BGJ398 mesylate or NVP-BGJ398 mesylate, is a pan FGFR kinase inhibitor, and is an orally bioavailable pan inhibitor of human fibroblast growth factor receptors (FGFRs) with potential antiangiogenic and antineoplastic activities. pan FGFR kinase inhibitor BGJ398 selectively binds to and inhibits the activities of FGFRs, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation, and the induction of tumor cell death. Infigratinib mesylate was approved in 2021 to treat adults with cholangiocarcinoma whose disease meets certain criteria.